Project Grant R21AR081933
Award Date
9/23/23
Completion Date
8/31/25
Dollars Obligated
$365K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
This $375,100 federal Project Grant award was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant funds a study to investigate the interplay between nucleic-acid-dependent phase separation and immune responses against cyclic GMP-AMP synthase (cGAS) in systemic lupus erythematosus (SLE). The research aims to determine how changes in the biophysical...
This federal Project Grant award of $216,113.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to characterize hematopoietic stem cell (HSC) impairment in a mouse model of systemic lupus erythematosus (SLE)-like disease. The research aims to understand how clinical SLE-like disease affects HSC activity, which may contribute to hematological...
The University of Colorado-Denver received a $367,900 Project Grant (R21AR082655) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant will fund research to develop novel formulations of the drug imatinib that can enhance its delivery and accumulation in the kidney to improve treatment of glomerular kidney diseases, including lupus nephritis. The research team will...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to investigate the role of Langerhans cells in regulating lymphatic function and immune tolerance in systemic lupus erythematosus (SLE). The $788,508 award to The Hospital for Special Surgery Fund, Inc. will fund a 5-year study to delineate the mechanisms by which Langerhans...
The Medical University of South Carolina (MUSC) has been awarded a $5,134,759 Cooperative Agreement from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a Phase II clinical trial evaluating the use of allogeneic mesenchymal stromal cells (MSCs) for the treatment of refractory lupus. The trial, titled "A Phase II Controlled Trial of Allogeneic Mesenchymal Stromal Cells for the Treatment of...
This Project Grant award of $405,350.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research aims to characterize lipid droplets in macrophage subsets and determine if manipulating lipid droplet content can shift macrophage function, with the goal of uncovering new therapeutic targets for systemic lupus erythematosus (SLE). The award recipient is The...
This $793,093 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research program) supports research to define the regulatory landscape of systemic lupus erythematosus (SLE) and cardiovascular disease (CVD) comorbidity. The research team at the Oklahoma Medical Research Foundation, with a sub-award to the University of California, San Diego, will conduct systematic studies in macrophage cells to identify genetic...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $715,957 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to Northwestern University to investigate the molecular mechanisms by which type I interferon supports the production and expansion of T peripheral helper (Tph) cells in systemic lupus erythematosus (SLE) patients. The research project aims to utilize cutting-edge biochemical, epigenetic, and genetic approaches to...
This federal Project Grant award of $329,304 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop effective atherosclerotic cardiovascular disease (ASCVD) preventive interventions for patients with lupus nephritis (LN). The key products and services to be delivered include: An implementation guide for clinicians to support decisions on tailoring ASCVD...
The Department of the Army Medical Command awarded a $750,000 Project Grant to The Trustees of Columbia University in the City of New York under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant aims to validate Systemic Lupus Erythematosus (SLE) virtual outcome measures through three specific objectives over a three-year period ending August 2024. Sub-awards were provided to six institutions, including the Oklahoma Medical Research Foundation and the...